Dr. Cohen Discusses Entrectinib in Head and Neck Cancer

Ezra Cohen, MD
Published: Wednesday, Oct 25, 2017



Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Entrectinib is a potent inhibitor of ROS1 and NTRK. In some cancers, Cohen explains, the NTRK gene will fuse with other elements, usually transcription factors, and can activate the cancer phenotype in multiple ways.

In a case of anaplastic thyroid cancer, the tumor had this NTRK3 fusion and within 10 days, the patient went from being dependent to being out of the hospital after being treated with entrectinib.
 


Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Entrectinib is a potent inhibitor of ROS1 and NTRK. In some cancers, Cohen explains, the NTRK gene will fuse with other elements, usually transcription factors, and can activate the cancer phenotype in multiple ways.

In a case of anaplastic thyroid cancer, the tumor had this NTRK3 fusion and within 10 days, the patient went from being dependent to being out of the hospital after being treated with entrectinib.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x